15 Dec Verify Brand’s Serialization History
It was 2001, and a large, global software company had all but given up hope that any physical security systems—foil holograms, color shifting inks or even special threads woven into proprietary packaging—could outsmart the organized counterfeiters selling its pirated software.
Out of patience and out of options, the software company asked us to assist them with a difficult numbering problem for labels that were intended to thwart counterfeiters. Physical deterrents had been ineffective. The software company needed a system that the pirates couldn’t mimic. They needed item-level serialization. This was, of course, long before serialization was on anyone’s radar, much less things such as DSCSA or EU FMD compliance.
The idea itself was simple: each package of software would carry a unique identifier, an alphanumeric code to be verified by the consumer at home, after purchase. In order to be successful, we needed to find a way to produce hundreds of millions of secure unique identifiers (sUIDs) with zero print errors. Given the scale of the project, even a .0001% error rate would yield thousands of phone calls from angry consumers who couldn’t activate their software.
Leveraging our experience as a supplier to the pharmaceutical industry and serialized bar code printer, we created a system where an image of every single sUID was captured with a camera after it was “born.” Next, that image was scanned by optical character recognition (OCR) software to recreate a digital number. Only sUIDs that appeared on both listsy—what we intended to produce and what we had in fact printedy—were 100 percent verified.
This process would become one of dozens of patent claims that we were granted over the next few years. By 2004 our efforts had coalesced into a bona fide business venture and Verify Brand was born.
Right around that time, we were invited to speak at the University of Georgia’s College of Pharmacy at the International Good Manufacturing Practices Conference. There, for the first time, we shared our success publicly, described our work and articulated a vision for the future. Not long after that, in what is perhaps an even more public starting point for the industry as a whole, Dr. Roger Johnston of The Los Alamos National Laboratory published a major paper. Previously, he had been charged with finding a solution to the devastating and rampant public health and economic crisis of bogus pharmaceutical products—ineffective and sometimes deadly counterfeit drugs that flooded U.S. and overseas markets.
Dr. Johnston’s 21-page summary report stated that no known physical deterrent, such as holograms, etc., could work for any meaningful length of time. Counterfeiters and pirates were simply too good—and too quick—at recreating the technologies and mimicking the security systems as soon as they were in place. In fact, holograms and other markers helped criminals by making their bogus products seem more legitimate. All but the most sophisticated and highly trained security personnel were fooled.
In conclusion, said Dr. Johnston, item-level serialization—which he described as “Call In the Numeric Token,” or CNT technology—was the only security system with proven effectiveness, especially on such massive scale. From our vantage point, the need for secure item level serialization in the pharmaceutical industry was obvious. Accordingly, we built our software in full compliance with crucial FDA guidelines and quality standards, such as Title 21 CFR Part 11.
At the same time, there were several other ideas gaining traction within both the pharmaceutical industry and at the FDA. One of those ideas was a known as e-pedigree, an online tracking system that records every transaction surrounding a pharmaceutical sale. In effect, it was data about data.
However, we remained huge proponents of item-level serialization. We’d seen what it could do in real-world applications, and had even worked with an ink jet printing partner to demonstrate proof of concept at the individual pill level. We did pioneering work on serialization, proving that truly random numbers are essential. Any other pattern or sequence—no matter how complex or seemingly random—can eventually be cracked. We developed schemas that were EPCIS compliant but not any longer than they needed to be, once again adding to our growing patent portfolio.
We were also an early participant with EPC Global and a member of the Health and Life Sciences Software Action Group, helping to set vital standards related to drug messaging and EPCIS repositories. We built EPCIS messaging standards right into our platform from the outset, building on our work with Ethicon’s surgical mesh, conclusively demonstrating that item-level serialization was practical, easily implemented and highly effective.
At the same time, other industries had taken note of our pioneering work in the pharmaceutical and medical sectors and shared our enthusiasm for item-level serialization. Suddenly, we found ourselves in demand with electronics and computer manufacturers, chemical companies and others who constantly battled supply chain diversion, counterfeiting and piracy. Our gold standard level of security and quality control, our built-in EPCIS compliance and our patented event source architecture—all developed while working within the pharmaceutical sphere—won clients over in other sectors, while the pharmaceutical industry awaited regulatory clarity.
In 2013, the federal government intervened with the passage of the DQSA legislation, ushering in a new era of item-level serialization within the pharmaceutical industry. On December 7, 2017, Verify Brand was acquired by OPTEL Group, a leading global provider of traceability systems for the pharmaceutical and medical device industries. This acquisition combines OPTEL’s experience in deploying characterization and data-capturing solutions in industrial environments with Verify Brand’s proven data management and analytics expertise.
At last, we are on the doorstep of this historic improvement to supply chain security and anti-counterfeit measures within our drug supply systems. Schedule a demo of our solution here.